組織簡介

The 4-year“Program for Translational Innovation of Biopharmaceutical Development”was jointly planned by Academia Sinica (AS), Ministry of Science and Technology (MOST), Ministry of Economic Affairs (MOEA), and Ministry of Health and Welfare (MOHW), and was launched in 2017.The overall goal of the program is to consolidate existing biomedical infrastructures, accelerate the commercialization of innovative technologies, and strengthen the biomedical industry in Taiwan. The program consists of two axes, the“Technology Supporting Platform Axis (TSPA)”, and the“Translational Clinical Axis”.The missions of TSPA are: (1) to promote effective integration of nationwide research facilities and resources; (2) to support research in biotechnology, genomics, medicines, and biopharmaceuticals by the provision of high-priced, high-throughput, and state-of-the-art instruments, along with professional analytical and consulting services; and (3) to help propagate advanced technologies and engage academics with industries. There are six platforms in TSPA as shown below, and all are open for service applications by researchers from local and international academic and industrial institutions.